MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis
By V. Kasivisvanathan, A. Rannikko, M. Borghi, V. Panebianco, L. Mynderse, M. Vaarala, A. Briganti, L. Budäus, G. Hellawell, R. Hindley and 31 more. New England Journal of Medicine, 2018
2,580 citations recorded by the source corpus.
Background Multiparametric magnetic resonance imaging (MRI), with or without targeted biopsy, is an alternative to standard transrectal ultrasonography–guided biopsy for prostate‐cancer detection in men with a raised prostate‐specific antigen level who have not undergone biopsy. However, comparative evidence is limited. Methods In a multicenter, randomized, noninferiority trial, we assigned men with a clinical suspicion of prostate cancer who had not undergone biopsy previously to undergo MRI, with or without targeted biopsy, or standard transrectal ultrasonography–guided biopsy. Men in the MRI‐targeted biopsy group underwent a targeted biopsy (without standard biopsy cores) if the MRI was suggestive of prostate cancer; men whose MRI results were not suggestive of prostate cancer were not offered biopsy. Standard biopsy was a 10‐to‐12–core, transrectal ultrasonography–guided biopsy. The primary outcome was the proportion of men who received a diagnosis of clinically significant cancer. Secondary outcomes included the proportion of men who received a diagnosis of clinically insignificant cancer. Results A total of 500 men underwent randomization. In the MRI‐targeted biopsy group, 71 of 252 men (28%) had MRI results that were not suggestive of prostate cancer, so they did not undergo biopsy. Clinically significant cancer was detected in 95 men (38%) in the MRI‐targeted biopsy group, as compared with 64 of 248 (26%) in the standard‐biopsy group (adjusted difference, 12 percentage points; 95% confidence interval [CI], 4 to 20; P=0.005). MRI, with or without targeted biopsy, was noninferior to standard biopsy, and the 95% confidence interval indicated the superiority of this strategy over standard biopsy. Fewer men in the MRI‐targeted biopsy group than in the standard‐biopsy group received a diagnosis of clinically insignificant cancer (adjusted difference, ‐13 percentage points; 95% CI, ‐19 to ‐7; P<0.001). Conclusions The use of risk assessment with MRI before biopsy and MRI‐targeted biopsy was superior to standard transrectal ultrasonography–guided biopsy in men at clinical risk for prostate cancer who had not undergone biopsy previously. (Funded by the National Institute for Health Research and the European Association of Urology Research Foundation; PRECISION ClinicalTrials.gov number, NCT02380027.)
Subfields: Pulmonary and Respiratory Medicine, Radiation
View Paper: https://www.semanticscholar.org/paper/6a075e344e4d6a67c65c6adef9f46020c5baa8af
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches (2022, background): “In recent years, the availability of novel molecular markers, as well as the introduction of advanced imaging techniques such as multiparametric magnetic resonance imaging (mpMRI) and prostate-specific membrane antigen positron emission tomography (PSMA-PET) scans have shifted the paradigm of prosta”
- EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. (2020, result): “In biopsy-naïve patients, the difference appears to be less marked and was not significant in the MRI-FIRST and 4M trials [41,42], whilst it was significant in the PRECISION trial [43].”
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. (2024, neutral): “In biopsy-naïve men, an MRI-based indication for biopsy after referral leads to lower rates of biopsy, fewer men diagnosed with PCa labelled as insignificant, and more men diagnosed with PCa labelled as csPCa [27,28] as compared with systematic biopsy alone.”
- “A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer” (2019, methodology): “Development and use of more specific tests such as Prostate Health Index, 4 K score, and risk calculators must be prioritised, as well as improving the diagnostic work-up with less invasive diagnostic methods such as magnetic resonance imaging [18].”
- Cancer statistics, 2023 (2023, background): “43,44 Black men benefit more from screening in general 45,46 and from the integration of personalized biomarkers because they are more likely to harbor genomically aggressive cancer, even with clinically low ‐ risk disease.”
- Cancer statistics, 2024 (2024, background): “39 Efforts are ongoing to revitalize beneficial prostate cancer screening while mitigating the harms from overdiagnosis and overtreatment through the use of molecular markers, magnetic resonance imaging ‐ targeted biopsy, 40,41 and active surveillance of low ‐ risk disease.”
- Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. (2019, result): “The proportion of men avoiding biopsy is almost twice that reported by the PROMIS and PRECISION trials—27% and 28%, respectively [9,10].”